1Department of Anaesthesia and Intensive Care Medicine, University of Wales College of Medicine, Cardiff, UK. 2Department of Anesthesiology, VA Medical Center and Medical College of Wisconsin, Milwaukee, Wisconsin, USA*Corresponding author: Department of Anaesthesiology, VA Medical Centre 112A, 5000 West National Avenue, Milwaukee, WI 53295, USA
This article is accompanied by Editorial I.
Accepted for publication: July 31, 2000
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Br J Anaesth 2001; 86: 511
Keywords: sedation; analgesics, 2-adrenoceptor agonist, clonidine
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
An important difference between clonidine and dexmedetomidine is their elimination half-life, which is nearly four times longer for clonidine than for dexmedetomidine.4 Therefore, dexmedetomidine is more titratable than clonidine, and recovery is more rapid.2 However, slower elimination may sometimes be desirable, especially in the intensive care situation, where a more gradual weaning from sedation and analgesia might be desired or beneficial.
Continuous i.v. clonidine has been evaluated for its morphine-sparing effects in treating postoperative pain,5 6 and in the postoperative period for complete pain control.5 One notable finding in these studies was a substantial haemodynamic effect (hypotension and bradycardia) coincident with the desired sedative and analgesic effects. In addition, these studies provided little information about the doseresponse relationship for analgesia, sedation and haemodynamic effects. The present placebo-controlled study in healthy volunteers evaluated three doses of clonidine that were predicted to have minimal cardiovascular effects, and evaluated several end-points, including sedation, cognitive function, analgesia and cardiorespiratory function.
![]() |
Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Subjects were asked to abstain from alcohol for 24 h and any oral intake for 6 h before the study. Each volunteer participated on four occasions separated by at least 7 days, but not more than 10 days. They were randomized to either placebo or one of three doses of clonidine. Treatments consisted of a loading dose of placebo or clonidine, 1, 2 or 4 µg kg1, given over a 15 min period and followed by a maintenance infusion of placebo or clonidine, 1, 2, or 4 µg kg1 h1, for a 45 min period. Monitoring involved ECG leads II and V5 for monitoring heart rate (HR) and cardiac conduction changes, non-invasive oscillometric arterial pressure measurement (mean arterial pressure, MAP), pulse oximetry for oxygen saturation (SpO2), and a nasal cannula for end-tidal carbon dioxide monitoring. The depth of hypnosis was monitored with a processed EEG (bispectral index system, BIS; Aspect Medical Systems, Newton, MA, USA). Two i.v. lines were placed in the non-dominant arm, one for infusion of clonidine and the other in a different vein for sampling for plasma clonidine concentration. The dominant hand was used to perform written tests and for immersion into ice water (cold pressor test).
After instrumentation and a 10 min rest period, baseline measurements (HR, MAP, SpO2, carbon dioxide and BIS) were collected. This was followed by a 5 min rest period, after which resting haemodynamics and end-tidal carbon dioxide were averaged during a 3 min sampling period. There followed the battery of tests to assess sedation, psychomotor performance and memory, and the cold pressor test. After all the baseline measurements and tests had been done, infusions were started with both investigators and subject blinded to the randomization code. Cardiorespiratory parameters were measured at the end of the loading dose (15 min), the end of infusion (60 min) and at 45 and 90 min of recovery, as well as during all cold pressor tests. BIS was recorded every 5 min throughout infusion and recovery. Assessments of sedation (Observer Assessment of Analgesia/Sedation (OAA/S) and a visual analogue scale for sedation (VASSEDATION)) and a self-rating of co ordination (visual analogue scale for coordination (VASCOORDINATION)) were taken at 5, 10 and 15 min during the loading dose and again at 60 min, just before drug termination. Psychomotor (Digital Symbol Substitution Test, DSST), cold pressor and memory tests were performed only at the end of the 60 min infusion period. After drug termination, all tests and assessments were repeated at 45 and 90 min of recovery.
Description of tests
There were three measures of sedation. The first was objective and measured from the processed EEG signal, which indicated the state of hypnosis (BIS). This was recorded continuously and noted at 5 min intervals throughout the study. The second measure was assessment by an independent observer (OAA/S) and was based on categories of responsiveness to verbal stimuli, speech, facial expression and eyes. Finally, visual analogue scales (VAS, scale 0100) were used to assess sedation and coordination by sliding a movable indicator line between the two end-points of the scale. The subject rated the level of sedation (VASSEDATION) on a scale in which the 0 end represented asleep and 100 represented wide awake; the coordination scale (VASCOORDINATION) had the descriptors clumsy at 0 and well coordinated at 100.
Psychomotor performance was tested using a DSST and memory function was determined from a word recall test (MEM). The DSST is a timed test of psychomotor performance (a different test form is given at each time point) with a chart of eight rows of digits in random sequence. There are nine written symbols, each with a corresponding numerical digit. The subject replaces the symbol with its corresponding number. Correct substitutions within a 90 s period were tallied for the score. The MEM test consisted of listening to a series of 16 unrelated words and immediately reciting as many as possible. The MEM test at the 90 min recovery point was different. Subjects did not listen to a new series of words, but rather they were asked to recall as many of the words as possible from the three previous lists, which had been given at baseline, 60 min of infusion and 45 min of recovery. This test is termed the comprehensive memory test (CMEM). In addition to tallying the total number recalled, the number recalled from each list was identified.
The cold pressor test consisted of immersing the subjects hand to the wrist in a constantly agitated ice/water mix for 1 min, and collecting haemodynamic variables and averaging them over the last 15 s of the test. Pain experienced due to the cold exposure was assessed by the subject using a visual analogue scale (VASPAIN) that had end-points of no pain (0) and worst pain imaginable (100).
Statistics
Data are expressed as mean (SD) except in graphical presentations, where standard error bars are used to reduce clutter. Repeated measures analysis of variance (ReANOVA) was used and post hoc analysis was with the Bonferroni test. The CMEM was a single test (not repeated over time), so Students t-test was used to determine differences between groups. Significance was established at P<0.05.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Sedation assessment
All three doses of clonidine produced significant sedation (BIS) compared with placebo (Figs 1 and 2). There was increasing sedation with increasing dose, but the BIS was unable to differentiate between 1 and 2 µg kg1 h1. After the 60 min infusion, the BIS number had decreased by 6, 17, 21 and 62% in placebo, 1, 2 and 4 µg kg1 h1. At 90 min recovery from clonidine 1 µg kg1 h1, the BIS had returned to baseline concentrations, but 90 min after the 2 and 4 µg kg1 h1 infusions there were still significant concentrations of sedation based on BIS. The OAA/S gave essentially identical results to the BIS during both infusion and recovery. Only slightly different results from the VASSEDATION tests were noted; a 23, 57, 60 and 84% reduction in score was recorded at the 60 min infusion time point for the four groups respectively. This test did not provide a statistically significant difference between placebo and clonidine 1 µg kg1 h1, though it did show a difference between placebo and clonidine 2 and 4 µg kg1 h1 and a similar recovery profile to the BIS and OAA/S.
|
|
|
|
|
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
With the recent development of the highly specific 2-agonist dexmedetomidine, there has been renewed interest in this class of drug for use in the perioperative period.2 3 79 These drugs offer both analgesia and sedation with little if any impairment of respiratory functiona combination that could be useful in the postoperative or ICU setting.5 In addition, dexmedetomidine2 and clonidine (on the basis of this study investigating infusions of duration 1 h) have the interesting property that they allow quick and easy arousal from sedation. This enabled the subjects (and presumably patients) to answer questions and to participate in testing. Clonidine has been investigated extensively for its analgesic and anaesthetic sparing qualities, but its long elimination half-life of 8.5 h4 makes its use for continuous i.v. sedation and analgesia difficult, and there is no consensus on appropriate dose regimens.
Rat studies have shown MAC (minimum alveolar concentration) reduction in this class of drugs to be mediated by central 2-adrenoceptors alone, without involvement of opioid and adenosine receptors.10 MAC reduction from clonidine is reported to be 40% in humans.11 Because of the incomplete MAC-sparing effects of clonidine, care must be taken when it is used as an adjuvant during anaesthesia, to ensure a depth that is adequate to avoid awareness.
Responses to very high i.v. doses of clonidine have been described. One study in postsurgical patients used 8 µg kg1 i.v. (which produced plasma clonidine concentrations of 2.5 ng ml1) followed by patient-controlled clonidine analgesia, and found this regimen to be associated with considerable and increasing sedation over the 600 min period of the study.1 This dose also produced a significant fall in blood pressure (>25 mm Hg). In an effort to avoid unnecessary haemodynamic effects, the present study examined lower doses of clonidine.
Clonidine doses up to 45 µg kg1 have been investigated frequently, though primarily for their anaesthetic-sparing effects in the intraoperative period and for their opioid-sparing effects in the postoperative period. Oral premedication with 5 µg kg1 has been used successfully to improve intraoperative haemodynamic stability and reduce anaesthetic11 and opioid requirements.2 A pre-emptive dose of 45 µg kg1 i.v. followed by infusion (plasma concentration approx. 1.7 ng ml1) has also been shown to have a morphine-sparing effect for postoperative analgesia.5 13 Several studies used similar dosing of clonidine to reduce morphine requirements and reported that sedation with clonidine was not greater than that of the morphine control.5 6 The present study achieved plasma concentrations above 1.5 ng ml1 during the 4 µg kg1 h1 infusion, which was associated with analgesia and good sedation that was easily overcome by calling the patients name in a normal or loud voice. The lower plasma concentrations studied in this protocol did not result in significant analgesia, but did provide easy arousal from sedation without impairing cognitive function.
A limitation of this research is that only healthy volunteers were studied with short-duration infusions and we cannot be certain that these findings translate to the patient population in pain or stressful settings. However, our findings seem to be consistent with patient studies in which patients received i.v. clonidine during the perioperative period.
The present study attempted to assess the depth of hypnosis using a processed EEG monitor. The BIS monitor provided an objective assessment of sedation and proved to be a sensitive correlate of dose. BIS findings were supported by the subjective, observer-assessed OAA/S measurement, so that bispectral analysis of EEG may be a useful assessment tool when using 2-agonists.
2-Agonists behave differently from other sedatives, seemingly producing something closer to sleep, as we recorded BIS numbers in the 30 s in a few volunteers, during which the infusion rate was 4 µg kg1 h1, and yet we were able to awaken them immediately to BIS numbers above 90 to perform tests. During general anaesthesia (or i.v. sedation with common drugs such as propofol and opioid/benzodiazepine combinations), BIS scores as low as this would be taken to indicate deep sedation or hypnosis and immediate waking would not be possible.14 Consistent with our previous study using dexmedetomidine, a rapid increase in the level of consciousness sufficient to perform neurocognitive tests is a unique characteristic of
2-agonist sedation.2
Clonidine has a low ratio of 2 to
1 activity in the rat brain (220:1),15 and this might result in some
1-receptor side-effects. In fact, i.v. boluses of clonidine can cause transient hypertension, and both
2- and
1-receptor agonism on vascular smooth muscle has been implicated.16 17 However, transient hypertension has not been seen in patients undergoing spinal surgery and receiving i.v. clonidine (5 µg kg1 followed by an infusion).5 In fact, significant decreases in MAP were noted and were associated with increased cumulative fluid volume in the postoperative period.5 In the present study, which used young healthy volunteers, cardiovascular changes were small. A recent study in a similar volunteer population with low-dose clonidine supports our findings.18 These volunteer studies support the hypothesis of De Kock and colleagues that clonidine produces analgesia at doses lower than those required to cause significant hypotension,13 and extend this hypothesis by demonstrating significant sedation without analgesia when using clonidine at lower doses. However, we cannot rule out the possibility that the presumed lower sympathetic tone in volunteers not in pain from surgery might contribute to the smaller decreases in arterial pressure noted in this protocol.
A limitation of this study is the short (1 h) duration of infusion of clonidine and the possibility that a steady state was not achieved. Although plasma concentrations of clonidine after the 15 min load and at the 60 min time point were identical for each infusion group, the effect site concentration may not have been equilibrated. The two lower infusion rates of clonidine were more likely to have achieved a steady state, based on stable BIS recordings during the last 15 min of the 1 h infusion. However, the 4 µg kg1 h1 infusion resulted in decreasing BIS values (at 45, 50, 55 and 60 min the average BIS was 64, 60, 58 and 56 respectively), suggesting that the effect sites had not achieved steady state.
The respiratory effects of clonidine have been much debated,1922 but the consensus appears to be that it is associated with little respiratory depression, and this study would confirm that. 2-Adrenoceptor agonists, although found throughout the brainstem, are not thought to have a specific role in central respiratory control.23 One potential respiratory problem with this class of drugs lies in the fact that they dry the mucous membranes. After the 4 µg kg1 h1 dose, volunteers consistently complained of a dry mouth. The drying of secretions suggests there might be a potential for effects on respiratory function through increased mucous viscosity and, consequently, plugging. If this class of drugs is to be used for postoperative sedation, this potential will have to be evaluated.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
2 Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg 2000; 90: 699705
3 Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000 (in press)
4 Davies DS, Wing LMH, Reid JL, Neill E, Tippett P, Dollery CT. Pharmacokinetics and concentrationeffect relationships of intravenous and oral clonidine. Clin Pharmacol Ther 1977; 21: 593601[ISI][Medline]
5 Bernard J-M, Hommeril J-L, Passuti N, Pinaud M. Postoperative analgesia by intravenous clonidine. Anesthesiology 1991; 75: 57782[ISI][Medline]
6 DeKock MF, Pinchon G, Scholtes JL. Intraoperative clonidine enhances postoperative morphine patient controlled analgesia. Can J Anaesth 1992; 39: 53744[Abstract]
7 Khan ZP, Munday IT, Jones RM, Thornton C, Mant TG, Amin D. Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. 1: Pharmacodynamic and pharmacokinetic interactions. Br J Anaesth 1999; 83: 37280
8 Thornton C, Lucas MA, Newton DEF, Doré CJ, Jones RM. Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. 2: Auditory and somatosensory evoked responses. Br J Anaesth 1999; 83: 3816
9 Thomson IR, Peterson MD, Hudson RJ. A comparison of clonidine with conventional preanesthetic medication in patients undergoing coronary artery bypass grafting. Anesth Analg 1998; 87: 2929[Abstract]
10 Segal IS, Vickery RG, Walton JK, Doze VA, Maze M. Dexmedetomidine diminishes halothane anesthetic requirements in rats through a postsynaptic alpha-2 adrenergic receptor. Anesthesiology 1988; 69: 81623
11 Ghignone M, Calvillo O, Quintin L. Anesthesia and hypertension: the effect of clonidine on perioperative hemodynamics and isoflurane requirements. Anesthesiology 1987; 67: 310[ISI][Medline]
12 Ghignone M, Quintin L, Duke PC, Kehler CH, Calvillo O. Effects of clonidine on narcotic requirements and hemodynamic response during induction of fentanyl anesthesia and endotracheal intubation. Anesthesiology 1986; 64: 3642[ISI][Medline]
13 DeKock M, Lavandhomme P, Scholtes JL. Intraoperative and postoperative analgesia using intravenous opioid, clonidine and lignocaine. Anaesth Intensive Care 1994; 22: 1521[ISI][Medline]
14 Glass PS, Bloom M, Kearse L, Rosow C, Sebel P, Manberg P. Bispectral analysis measures sedation and memory effects of propofol, midazolam, isoflurane, and alfentanil in healthy volunteers. Anesthesiology 1997; 86: 83647[ISI][Medline]
15 Virtanen R, Savola J-M, Saano V, Nyman L. Characterization of selectivity, specificity and potency of medetomidine as alpha2-adrenoceptor agonist. Eur J Pharmacol 1988; 150: 914[ISI][Medline]
16 Dyck JB, Shafer SL. Dexmedetomidine pharmacokinetics and pharmacodynamics. Anaesth Pharm Rev 1993; 1: 23845
17 Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. Anesthesiology 1992: 77; 113442[ISI][Medline]
18 Bischoff P, Mahlstedt D, Blanc I, Esch JS. Quantitative topographical electroencephalographic analysis after intravenous clonidine in healthy male volunteers. Anesth Analg 1998; 86: 2027[Abstract]
19 Penon C, Ecoffey C, Cohen SE. Ventilatory response to carbon dioxide after epidural clonidine injection. Anesth Analg 1991; 72: 7614[Abstract]
20 Ooi R, Pattison J, Feldman SA. The effects of intravenous clonidine on ventilation. Anaesthesia 1991; 46: 6323[ISI][Medline]
21 Benhamou D, Veillette Y, Narchi P, Ecoffey C. Ventilatory effects of premedication with clonidine. Anesth Analg 1991; 73: 799803[Abstract]
22 Zornow MH. Ventilatory, hemodynamic and sedative effects of the a2 adrenergic agonist, dexmedetomidine. Neuropharmacology 1991; 30: 106571[ISI][Medline]
23 Belleville JP, Ward DS, Bloor BC, Maze M. Effects of intravenous dexmedetomidine in humans. Anesthesiology 1992; 77: 112533[ISI][Medline]